Antiseizure potential of the triple T‐type calcium channel blocker ACT ‐709478 (apinocaltamide) in rodent models
Abstract
Objective: T‐type Ca 2+ channels in the brain contribute to the generation of spike‐and‐wave discharges (SWDs). Absence seizures are defined by the occurrence of SWDs and are associated with impairment of consciousness. ACT‐709478 is a selective and highly potent blocker of the low‐voltage‐activated T‐type Ca 2+ channels, Ca v 3.1, Ca v 3.2, and Ca v 3.3, with no relevant activity on other targets. Our aim was to investigate the efficacy of ACT‐709478 in reducing absence‐like and other types of seizures in rodents. Methods: We studied the effect of oral ACT‐709478 on SWDs in two models of absence‐like epilepsy, Wistar Albino Glaxo from Rijswijk (WAG/Rij) rats and Genetic Absence Epilepsy Rats from Strasbourg (GAERS), and compared it to first‐line monotherapy. We also assessed the potential of ACT‐709478 to reduce generalized convulsive seizures in audiogenic seizure‐sensitive (AGS) mice and in the maximal electroshock threshold test (MEST) in mice, as well as in one model of focal onset seizures, the amygdala kindling rat model. We tested combinations of ACT‐709478 with the broadly used first‐line medication valproate in AGS mice. Results: ACT‐709478 suppressed SWDs in WAG/Rij rats and GAERS with efficacy equivalent to or superior to that of first‐line monotherapy. ACT‐709478 also reduced the severity of generalized convulsive seizures in the AGS mouse model and the MEST in mice, albeit at higher concentration. ACT‐709478 had synergistic effects against generalized convulsive seizures, when combined with valproate, and had no effect on focal onset seizures. Significance: Based on its efficacy profile in rodent models, ACT‐709478 represents a promising drug candidate for the treatment of absence epilepsy such as childhood absence epilepsy or syndromes featuring SWDs. It could possibly also be beneficial for epileptic syndromes presenting with additional seizure types.Keywords
This publication has 50 references indexed in Scilit:
- The pharmacological treatment of epilepsy in adultsEpileptic Disorders, 2023
- Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic DrugCNS Drugs, 2020
- Role for T-type Ca2+ channels in sleep wavesPflügers Archiv - European Journal of Physiology, 2014
- Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophreniaHuman Psychopharmacology: Clinical and Experimental, 2013
- Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variantsAnnals of Neurology, 2007
- Mutational analysis ofCACNA1Gin idiopathic generalized epilepsyHuman Mutation, 2007
- Genetic Models of Absence Epilepsy in the Rat2006
- Calcium currents in pyramidal CA1 neurons in vitro after kindling epileptogenesis in the hippocampus of the ratNeuroscience, 1996
- The WAG/Rij rat model for absence epilepsy: age and sex factorsEpilepsy Research, 1987
- Spontaneous paroxysmal electroclinical patterns in rat: A model of generalized non-convulsive epilepsyNeuroscience Letters, 1982